Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Gregory Michael Cote, M.D.

Co-Author

This page shows the publications co-authored by Gregory Cote and Edwin Choy.
Connection Strength

4.852
  1. A Phase 1 Study of Nilotinib Plus Radiation in High-Risk Chordoma. Int J Radiat Oncol Biol Phys. 2018 12 01; 102(5):1496-1504.
    View in: PubMed
    Score: 0.793
  2. Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience. Oncologist. 2018 02; 23(2):234-242.
    View in: PubMed
    Score: 0.744
  3. Role of epigenetic modulation for the treatment of sarcoma. Curr Treat Options Oncol. 2013 Sep; 14(3):454-64.
    View in: PubMed
    Score: 0.564
  4. Update in treatment and targets in Ewing sarcoma. Hematol Oncol Clin North Am. 2013 Oct; 27(5):1007-19.
    View in: PubMed
    Score: 0.561
  5. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. Eur J Cancer. 2020 02; 126:21-32.
    View in: PubMed
    Score: 0.219
  6. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 2015 Apr 15; 121(8):1223-30.
    View in: PubMed
    Score: 0.154
  7. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014 Nov 05; 14:813.
    View in: PubMed
    Score: 0.153
  8. Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1. PLoS One. 2014; 9(7):e101283.
    View in: PubMed
    Score: 0.149
  9. Clinical Utility of Anchored Multiplex Solid Fusion Assay for Diagnosis of Bone and Soft Tissue Tumors. Am J Surg Pathol. 2021 08 01; 45(8):1127-1137.
    View in: PubMed
    Score: 0.061
  10. Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. Nat Med. 2021 02; 27(2):289-300.
    View in: PubMed
    Score: 0.059
  11. The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies. Life Sci Alliance. 2021 02; 4(2).
    View in: PubMed
    Score: 0.059
  12. LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma. Cell Rep. 2020 Apr 14; 31(2):107539.
    View in: PubMed
    Score: 0.056
  13. LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma LIN28B Control of EWS-FLI1 Stability. Cell Rep. 2020 03 31; 30(13):4567-4583.e5.
    View in: PubMed
    Score: 0.056
  14. MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma. Sci Rep. 2020 03 10; 10(1):4409.
    View in: PubMed
    Score: 0.055
  15. Prognostic Factors in Dedifferentiated Chondrosarcoma: A Retrospective Analysis of a Large Series Treated at a Single Institution. Sarcoma. 2019; 2019:9069272.
    View in: PubMed
    Score: 0.054
  16. Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. Radiother Oncol. 2019 08; 137:61-70.
    View in: PubMed
    Score: 0.052
  17. Spindle and Round Cell Sarcoma With EWSR1-PATZ1 Gene Fusion: A Sarcoma With Polyphenotypic Differentiation. Am J Surg Pathol. 2019 02; 43(2):220-228.
    View in: PubMed
    Score: 0.051
  18. Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):52-61.
    View in: PubMed
    Score: 0.050
  19. Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11. Sci Rep. 2018 Aug 09; 8(1):12107.
    View in: PubMed
    Score: 0.050
  20. Clinicopathologic characteristics of poorly differentiated chordoma. Mod Pathol. 2018 08; 31(8):1237-1245.
    View in: PubMed
    Score: 0.048
  21. Secondary Acute Leukemia in Sarcoma Patients: A Population-Based Study. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):687-694.
    View in: PubMed
    Score: 0.047
  22. An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. J Hematol Oncol. 2017 05 15; 10(1):107.
    View in: PubMed
    Score: 0.046
  23. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. Oncotarget. 2017 May 02; 8(18):30276-30287.
    View in: PubMed
    Score: 0.045
  24. Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11. Sci Rep. 2017 03 06; 7:43941.
    View in: PubMed
    Score: 0.045
  25. Clinical outcomes for patients after surgery and radiation therapy for mesenchymal chondrosarcomas. J Surg Oncol. 2016 Dec; 114(8):982-986.
    View in: PubMed
    Score: 0.044
  26. miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo. Mol Oncol. 2017 02; 11(2):151-166.
    View in: PubMed
    Score: 0.044
  27. Preoperative radiation therapy combined with radical surgical resection is associated with a lower rate of local recurrence when treating unifocal, primary retroperitoneal liposarcoma. J Surg Oncol. 2016 Dec; 114(7):814-820.
    View in: PubMed
    Score: 0.044
  28. The Width of the Surgical Margin Does Not Influence Outcomes in Extremity and Truncal Soft Tissue Sarcoma Treated With Radiotherapy. Oncologist. 2016 10; 21(10):1269-1276.
    View in: PubMed
    Score: 0.043
  29. Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro. Sci Rep. 2016 04 29; 6:25239.
    View in: PubMed
    Score: 0.042
  30. Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray. J Orthop Res. 2016 09; 34(9):1606-12.
    View in: PubMed
    Score: 0.042
  31. NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function. Br J Pharmacol. 2016 Feb; 173(3):613-26.
    View in: PubMed
    Score: 0.042
  32. Clinical and biological significance of PIM1 kinase in osteosarcoma. J Orthop Res. 2016 07; 34(7):1185-94.
    View in: PubMed
    Score: 0.041
  33. CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma. Sci Rep. 2015 Jun 16; 5:11365.
    View in: PubMed
    Score: 0.040
  34. Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. Oncotarget. 2015 May 10; 6(13):11139-49.
    View in: PubMed
    Score: 0.040
  35. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo. Gynecol Oncol. 2015 Apr; 137(1):134-42.
    View in: PubMed
    Score: 0.039
  36. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer. 2014 Sep 19; 14:681.
    View in: PubMed
    Score: 0.038
  37. Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential. Oncoimmunology. 2014; 3(8):e954467.
    View in: PubMed
    Score: 0.038
  38. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014 Jul; 2(7):690-698.
    View in: PubMed
    Score: 0.037
  39. Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma. PLoS One. 2014; 9(4):e93996.
    View in: PubMed
    Score: 0.037
  40. Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma. J Orthop Res. 2014 May; 32(5):695-701.
    View in: PubMed
    Score: 0.036
  41. Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. Cancer Lett. 2014 Jan 01; 342(1):104-12.
    View in: PubMed
    Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.